Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
FLGT 
Fulgent Genetics Inc (FLGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: FLGT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $33.67
1 Year Target Price $33.67
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.89% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 859.06M USD | Price to earnings Ratio - | 1Y Target Price 33.67 |
Price to earnings Ratio - | 1Y Target Price 33.67 | ||
Volume (30-day avg) 3 | Beta 0.65 | 52 Weeks Range 14.57 - 31.04 | Updated Date 12/6/2025 |
52 Weeks Range 14.57 - 31.04 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.22 | Actual 0.14 |
Profitability
Profit Margin -13.62% | Operating Margin (TTM) -18.26% |
Management Effectiveness
Return on Assets (TTM) -3.63% | Return on Equity (TTM) -3.92% |
Valuation
Trailing PE - | Forward PE 7.94 | Enterprise Value 512124924 | Price to Sales(TTM) 2.72 |
Enterprise Value 512124924 | Price to Sales(TTM) 2.72 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA -4.34 | Shares Outstanding 30912392 | Shares Floating 20646387 |
Shares Outstanding 30912392 | Shares Floating 20646387 | ||
Percent Insiders 32.7 | Percent Institutions 57.21 |
Upturn AI SWOT
Fulgent Genetics Inc
Company Overview
History and Background
Fulgent Genetics, Inc. was founded in 2011. It focuses on providing genetic testing services to physicians and patients. The company has evolved from offering a limited menu of tests to a comprehensive platform, expanding its capabilities through technology development and strategic acquisitions.
Core Business Areas
- Genetic Testing Services: Offers a range of genetic tests, including single-gene tests, comprehensive panels, and exome sequencing, covering various medical conditions.
- COVID-19 Testing: During the pandemic, Fulgent provided high-throughput COVID-19 testing services, contributing significantly to its revenue. This segment is in decline.
- Biopharma Services: Fulgent provides genetic testing services that are tailored for biopharmaceutical companies to accelerate the drug discovery and development process.
Leadership and Structure
Ming Hsieh is the Chairman and CEO. The company has a typical corporate structure with departments for R&D, sales, operations, and finance.
Top Products and Market Share
Key Offerings
- Next Generation Sequencing (NGS): Fulgent's NGS platform offers comprehensive genetic information. NGS accounts for a significant portion of Fulgentu2019s revenues. Competitors include Illumina (ILMN), Thermo Fisher Scientific (TMO), and Quest Diagnostics (DGX).
- Expanded Carrier Screening (ECS): Offers testing to determine the risk of passing on inherited genetic conditions to offspring. Revenue contribution not precisely available. Competitors include Myriad Genetics (MYGN) and Natera (NTRA).
- Oncology Testing: Offers panels and tests specific to various types of cancer to aid in treatment decisions. No precise market share data available. Competitors: Exact Sciences (EXAS), Guardant Health (GH).
Market Dynamics
Industry Overview
The genetic testing industry is growing, driven by technological advancements, increased awareness, and demand for personalized medicine. It faces regulatory and reimbursement challenges.
Positioning
Fulgent is positioned as a provider of comprehensive and cost-effective genetic testing services, especially through its NGS platform. Its competitive advantage lies in its technology platform and operational efficiency.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of dollars by 2030. Fulgent is positioned to capture a portion of this TAM through its comprehensive testing services.
Upturn SWOT Analysis
Strengths
- Comprehensive test menu
- Proprietary technology platform
- High-throughput capacity
- Competitive pricing
Weaknesses
- Reliance on COVID-19 testing revenue in the past
- Fluctuations in testing volumes and pricing.
- High competition
Opportunities
- Expanding partnerships with biopharmaceutical companies
- Growth in international markets
- Increasing demand for personalized medicine
- Growing adoption of genetic testing
Threats
- Regulatory changes
- Reimbursement pressures
- Increased competition
- Economic downturns
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- DGX
- EXAS
- NTRA
Competitive Landscape
Fulgent has a competitive edge in pricing and operational efficiency, but lags behind larger competitors in terms of market presence and brand recognition.
Major Acquisitions
Inform Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expanded Fulgent's footprint in the diagnostics space, adding anatomical pathology capabilities and expertise.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by the expansion of genetic testing services and, significantly, by COVID-19 testing.
Future Projections: Future growth is expected to be driven by new product introductions, partnerships, and the increasing adoption of genetic testing, specifically in oncology and preventative health.
Recent Initiatives: Recent initiatives include expanding partnerships with biopharmaceutical companies, and investing in R&D for new test offerings. The company also made some key acquisitions.
Summary
Fulgent Genetics is in a competitive sector. The company leveraged its technical abilities to secure strong revenue from COVID-19 testing during the pandemic. Its current focus on its genetic testing services will drive growth. It faces the challenges of evolving reimbursement landscape and competition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulgent Genetics Inc
Exchange NASDAQ | Headquaters El Monte, CA, United States | ||
IPO Launch date 2016-09-29 | Chairman & CEO Mr. Ming Hsieh | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1313 | Website https://www.fulgentgenetics.com |
Full time employees 1313 | Website https://www.fulgentgenetics.com | ||
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.